Hexarelin

Hexarelin is a synthetic hexapeptide growth hormone secretagogue with high affinity for ghrelin receptors. It has been shown to have cardioprotective effects that are independent of GH release, possibly through direct effects on cardiac cells. Clinical trials have been conducted for cardiac protection.

PubMed results: 288 · Human studies: 168 · Animal studies: 274

Ranges reflect protocols studied in published research and animal-model extrapolation. Presented for research purposes only, not a recommendation or instruction for human use.

• Subcutaneous — standard range 100-200 mcg, 1-3 times daily

55-70 minutes (moderate confidence)

• Growth hormone secretagogue activity (Strong preclinical): Hexarelin is a synthetic hexapeptide GHS with high affinity for ghrelin receptors; research demonstrates robust stimulation of pulsatile GH release in experimental and early clinical models
• Cardioprotective effects independent of GH (Moderate clinical): Studies have examined cardioprotective actions of hexarelin that appear partly independent of systemic GH elevation, including research on direct cardiac-cell and ischemia-related pathways
• Cardiac protection clinical research (Limited): Clinical trial programs have investigated hexarelin in cardiac-protection contexts, though development has remained research-oriented without broad regulatory approval for this use

• Transient GH-axis related symptoms — Mild, Common. As with other growth hormone secretagogues, research observations include mild effects consistent with acute GH/IGF-axis activation such as flushing or transient fatigue in some study participants
• Increased appetite (ghrelin-pathway related) — Mild, Uncommon. Ghrelin-receptor agonism can theoretically influence appetite signaling; appetite changes have been noted with related GHS peptides though hexarelin-specific rates are less well quantified
• Injection site reactions — Mild, Anecdotal. Parenteral peptide research administration is associated with mild local injection-site reactions in general GHS literature

• Active malignancy / IGF-axis concerns (Theoretical / Preclinical): GH secretagogue activity that elevates GH and downstream IGF-1 raises theoretical concern in active cancer research settings where growth-factor signaling is undesirable
• Uncontrolled diabetes or significant insulin resistance research cautions (Theoretical / Preclinical): GH-axis activation can antagonize insulin action in metabolic research models, so GHS peptides are studied cautiously where glycemic control is a primary concern

Lyophilized (powder): Refrigerated (2-8°C), Up to 24 months. Light sensitive: yes, store dark

Reconstituted (solution): Refrigerated (2-8°C), 4-6 weeks. Solvent: Bacteriostatic water